Age-Related Macular Degeneration
Conditions
Brief summary
The purpose of this clinical trial is to evaluate the safety and clinical effectiveness of intravitreal bevacizumab (Lumiere®) in the single-dose form, for the treatment of patients with wet AMD.
Detailed description
Age-related macular degeneration is the main cause of severe vision loss in patients over 65 years of age. There is solid evidence of the efficacy and safety of bevacizumab in the treatment of wet AMD. However, it has not been registered for such indication yet. In response to the need for a proper adaptation, Lumiere® has been developed in a single-dose, sterile dosage containing bevacizumab 5 mg/vial in 0.2 mL injectable solution. This adaptation is intended to assure intravitreal administration avoiding the risk of contamination and potential adverse consequences, such as endophthalmitis and blindness, associated to reutilization or repackaging of bevacizumab vials for oncological use.
Interventions
DRUGBevacizumab (Lumiere®)
The first three doses of bevacizumab (Lumiere®) were administered via intravitreal injection on a monthly basis. A safety evaluation was conducted in the first month. Following the first three doses, continuation of the treatment (up to 6 doses) was decided according to response.
Sponsors
Laboratorio Elea Phoenix S.A.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Open label, multicenter study for evaluating the safety and clinical effectiveness of intravitreal bevacizumab
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients over 50 years of age diagnosed with wet age-related macular degeneration having indication of antiangiogenic therapy. * Both genders. * Subjects able to give informed consent.
Exclusion criteria
* Patients with contraindication to receive bevacizumab: * Hypersensitivity to the active ingredient or to some of the formula excipients. * Hypersensitivity to products derived from CHO cells or to other human recombinant antibodies or humanized antibodies. * Patients having received intravitreal antiangiogenic therapy prior to wet AMD treatment. * Patients receiving previous systemic antiangiogenic therapy. * Wet AMD in the healing period or disciform scar. * Pregnant, breastfeeding or childbearing-aged women. * Any person with choroidal neovascularization not associated to wet AMD. * History of retinal or intraocular surgery in the affected eye in the last three months. * Vitrectomy in the affected eye. * Any significant ocular infection, active or suspected, having compromised or able to compromise the eye to be studied. * Ocular inflammatory disease. * Myopia exceeding -8 diopters. * Extensive subfoveal subretinal hemorrhage \> 2 papillary diameter (PD). * Coexistence of other severe ocular diseases: uncontrolled ocular hypertension, terminal glaucoma, diabetic retinopathy, retinal vein thrombosis, optic atrophy. * History of stroke or myocardial infarction in the last 6 months. * Patients with coagulopathies. * Patients physically or mentally disabled to participate in such visual tests.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events codified using MedDRA. | 6 months | Register reports of drug related adverse events and compare them with prevalence in the literature after intravitreal bevacizumab (Lumiere®) in the single-dose form, for the treatment of patients with neovascular AMD. |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with changes in visual acuity using the ETDRS charts in patients with wet AMD. | 6 months |
| Number of participants with changes in retinal thickness as assessed by OCT in patients with wet AMD. | 6 months |
Countries
Argentina
Outcome results
None listed